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Abstract
The efficacy of copper aspirinate against thrombotic diseases has been tested
in animal models. The results show that copper aspirinate following ig pretreatment
for 7 days at 0.012mmol/kg markedly prolonged the bleeding time and inhibited the
mortality induced by arachidonic acid (AA) in mice. On cereral ischemia model,
pretreatment with 0.018mmol/kg copper aspirinate ig significantly increased
survival of animals and the density of intact hippocampal CA1 cells,and decreased
brain calcium concentration. Its anticerebral ischemia activity was superior to or
equal to nimodipine. It is,therefore,suggested that copper aspirinate is very promis-
ing in becoming an antithrombotic drug in preventing and treating thrombotic dis-
eases.
1. Introduction
Copper aspirinate is a copper complex of aspirin (see Fig. l) and has been
demonstrated to be more active as an antiinflammatory agent and less irritant tom
the digestive tract than aspirin [1][2]. Moreover it has,contrary to aspirin,antiulcer
activity [3][4]. Consequently it is recommended that copper aspirinate should be
clinically used to treat arthritic and other degenerative diseases. Recently we dis-
covered that it possesses much greater efficacy than aspirin against arachidonic acid
(AA) induced platelet aggregation [5],which suggests that copper aspirinate may
be a potential antithrombotic drug. In order to explore its usage in the prevention
and therapy of thromboembolic disorders related to undue 3ggregation of platelets,
we have examined its antithrombotic and anticerebral ischemia activities in animal
models,and report our results here.
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Fig.1 The chemical structure of copper aspirinate
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2. Experimental
Copper aspirinate was synthesized by a published method [3] and an aqueous
suspension in 5% propylene glycol and 1.4% polyvinyl alcohol was prepared just be-
fore administration. Groups of 20 to 25g ICR mice and 50 to 70g Mongolian gerbils
of either sex were used as experimental animals,and aspirin or nimodipine was se-
lected for comparison with copper aspirinate. Data obtained from the experiments
were analyzed by the t-test.
Effect of copper aspiri.ate on te tail bleeding time
Groups of 10 ICR mice were given copper aspirinate, aspirin or the vehicle
intragastrically (ig) for 7 days,and then the tail bleeding time of each group was
measured using Wang’s method [6]. Results are given in Table 1.
Effect of co,per a$tiriat o mortality caused by tromboi
Groups of 30 IRC micofter administrated with copper aspirinato or aspirin or vehi-
cle ig for 7 days, were injected with 80mg/kg AA in the tail vein to induce
thrombosis [7] ,the number of mice dying in each group was recorded and the mor-
tality calculated (Tal’ 2).
Effect of copper as/ ate on cerebral ischemia injury
Groups of gerils were treated with copper aspirinate or vehicle by the ig route or
with nimodipine by the ip (intraperitoneal) route for 7 days just before cerebral
ischemia injury was produced by occlusion of the bilateral carotid arteries followed
by reperfusion. Ischemia caused by occlusion is similar to that caused by thrombosis
in man. For gerbils following 20 min occlusion and one day of reperfusion,the death
number of each group within 24 hours was determined,and parietotemporal cortex
was dissected out for the determination of calcium and water content by means of
the documented method in the literature [8]. For gerbils following 10min occlusion
and 7 day reperfusion, the density of neurons in the hippocamus CA1 sector, in
terms of the number of intact neurons in two fields vision,was determined under a
photomicroscope according to a known method [9]. The results were presented in
Tables 3,4 and 5.
Table 1. Effect of 0.012mmol/kg copper aspirinate and O.056mmol/kg aspirin ig on
tail bleeding time,x-+ s, n 10, P <0.05 vs control
GrouP B!eed,tirne ,(min)
control 11.6 _+ 1.7
Aspirin 13.3 +- 3.6
Copper aspirinate 17.8 :t 3.7*
Table 2 Effect of 0.012mmol/kg copper aspirinate and O.056mmol/kg aspirin ig on
the mortality caused by AA,x:l:s,n=30,**P<0.01 vs control
G’rou’p Mortality
Con tr01 87%
Aspirin 27%**
Copper 8spirinate 13%**
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Table 3. Effect of O.018mmol/kg ig copper aspirinate and O.024mmol/kg ip
nimodipine on the mortality of gerbils after ischemia, P<O.05 vs control
Group number of animals Mortality
Control 15 33%
Nimodipine 18 6%
Copper aspirinate 14 7%
Table 4 Effect of 0.018mmol/kg ig copper aspirinate and O.024mmol/kg ip nimodipine
on brain water and calcium content in gerbils following ischemia,x+ s, n=7,
*P<0.01 vs control
Group H=O(%) Ca z+(/ mol/g wet wt)
Control 75.5 +- 2.08
Nimodipine 69.8 +- 2.08
Copper aspirinate 75.8 +- 0.68
4.2 +/- 0.88
1.9 +/- 0.60-
1.3 + 0.69
Table 5. Number of hippocampal CA1 cells remaining in cerebal ischmia gerbils
pretreated with 0.018mmol/kg ig copper aspirinate or O.024mmol/kg ip
nimodipine, x+s,n=6, ’P<0.01 vs control
Group Number of cell
Control
Nimodipine
Copper aspirinate
38.3 + 14.3
63.2 + 14.9
76.6 + 10.8-
3. Results and Disscussion
Effects of copper aspirinate on the tail bleeding time and on the mice mortality
caused by AA are listed,respectively, in Table 1 and 2. These data show that ig
administration of 0.012mmol/kg copper aspirinate for 7 days,significantly prolonged
bleeding time and inhibited AA-induced mortality. The bleeding time of copper
aspirinate-treated group was prolonged to 17.8 min from 11.6 min for the control
group but aspirin showed only a non-significant tendency to prolong bleeding time
at a dose of O.056mmol/kg. This result is consistent with the known observation
that aspirin lacks the ability to prolong bleeding time although it is a typical
antiplatelet drug. Mortality of mice was decreased from 87% for the control group
to 13% by copper aspirinate but to 27% by aspirin. Bleeding time of damaged blood
vessels is closely related to the thrombosis at damaged sites. It is,therefore,obvious
that copper aspirinate possesses a much higher antithrombotic activity than aspirin
Data presented in Table 3 show that the group of gerbils treated with copper
aspirinate prior to ischemia had a greater survival than the vehicle-treated
group,while there was no significant difference in mortality between groups of cop-
per aspirinate and nimodipine,mortality being 7% and 6%,respectively. From changes
in the brain calcium content during ischemia and reperfusion (see Table 4),copper
aspirinate was found to be very effective in lowering the brain calcium
concentration of gerbils,exhibiting an anti-overloaded calcium effect. This effect
of copper aspirinate at O.018mmol/kg ig seems to be greater than that of nimodipine at
O.O24mmol/kg ip. However no significant differences in brain water content were
observed among these groups. As shown in Table 5, O.O18mmol/kg ig copper
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aspirinate,similar to O.024mmol /kg ip nimodipine,markedly increased the neural cell
density in the CA1 sector of the hippocampus of pretreated animals. This means
that treatment of copper aspirinate could protect hippocampal CA1 cells from dam-
age by ischemia.
Ba;ed on the decreased mortality,decreased calcium content and increased neural
density we conclude that the anticerebral ischemia effects of copper aspirinate are
comparable to that of nomidipine in spite of the difference in administration route
between these two drugs in our experiments.
It has been shown in our previous studies [4] that copper aspirinate
significantly increases PGIzin plasma while inhibiting synthesis of TXAz,in constrast
to aspirin which can only decrease the formation of TXA=and to nimodipine which
acts as a vasodilator. PGIz is known to be a powerful vasodilator. So, copper
aspirinate is expected to exhibit both effect of aspirin as an antiplatelet drug and
of nimodipine as a vasodilator. Therefore copper aspirinate will become a more ef-
fective drug in preventing and treating thrombotic diseases, particularly cerebral
ischemia companied hy abnormalities of platelet aggregation.
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